1. Home
  2. XPER vs ALT Comparison

XPER vs ALT Comparison

Compare XPER & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XPER
  • ALT
  • Stock Information
  • Founded
  • XPER 1990
  • ALT 1997
  • Country
  • XPER United States
  • ALT United States
  • Employees
  • XPER N/A
  • ALT N/A
  • Industry
  • XPER Semiconductors
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • XPER Technology
  • ALT Health Care
  • Exchange
  • XPER Nasdaq
  • ALT Nasdaq
  • Market Cap
  • XPER 463.5M
  • ALT 472.3M
  • IPO Year
  • XPER 2003
  • ALT N/A
  • Fundamental
  • Price
  • XPER $8.87
  • ALT $6.43
  • Analyst Decision
  • XPER Strong Buy
  • ALT Strong Buy
  • Analyst Count
  • XPER 3
  • ALT 7
  • Target Price
  • XPER $19.00
  • ALT $20.83
  • AVG Volume (30 Days)
  • XPER 282.4K
  • ALT 2.0M
  • Earning Date
  • XPER 02-26-2025
  • ALT 02-27-2025
  • Dividend Yield
  • XPER N/A
  • ALT N/A
  • EPS Growth
  • XPER N/A
  • ALT N/A
  • EPS
  • XPER N/A
  • ALT N/A
  • Revenue
  • XPER $508,559,000.00
  • ALT $52,000.00
  • Revenue This Year
  • XPER N/A
  • ALT N/A
  • Revenue Next Year
  • XPER $2.28
  • ALT N/A
  • P/E Ratio
  • XPER N/A
  • ALT N/A
  • Revenue Growth
  • XPER N/A
  • ALT N/A
  • 52 Week Low
  • XPER $6.89
  • ALT $5.28
  • 52 Week High
  • XPER $12.29
  • ALT $14.84
  • Technical
  • Relative Strength Index (RSI)
  • XPER 39.39
  • ALT 42.82
  • Support Level
  • XPER $8.83
  • ALT $6.06
  • Resistance Level
  • XPER $9.34
  • ALT $7.10
  • Average True Range (ATR)
  • XPER 0.27
  • ALT 0.36
  • MACD
  • XPER -0.01
  • ALT 0.03
  • Stochastic Oscillator
  • XPER 16.28
  • ALT 33.33

About XPER Xperi Inc.

Xperi Inc consumer and entertainment technology company. Its offering comprises a portfolio of software and services. Its business is divided into four categories based on the products delivered and customers served: Pay-TV, Consumer Electronics, Connected Car, and Platform Solutions. It generates the majority of its revenue from the Consumer Electronics segment.

About ALT Altimmune Inc.

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Share on Social Networks: